There were 1,592 press releases posted in the last 24 hours and 426,332 in the last 365 days.

Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016

BOSTON, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that the Company will host an R&D Day on Thursday, November 17, 2016, from 1:00 p.m. to 3:00 p.m. ET at Lotte Palace Hotel in New York City.

During the R&D day, Paratek’s management team and opinion leaders in the field of antibiotics development and infectious disease will discuss progress of the clinical development program for omadacycline, including the following:

  • Provide a company update
  • Discuss the company’s efforts to advance clinical development for omadacycline’s use in UTI
  • Report results from additional registration enabling Phase 1 studies
  • Clinical unmet needs in ABSSSI, CABP and UTI and the value of an IV and Oral treatment option

Speakers will include:

Keith Rodvold, Pharm D
University of Illinois at Chicago
Chicago, IL

J. Scott Overcash, MD
Grossmont Emergency Medical Group
San Diego, CA

Tom Lodise, Pharm D, PhD
Albany College of Pharmacy and Health Sciences
Albany, NY

Alpesh Amin, MD
University of California,
Irvine, CA

Webcast Information 
A live webcast of the R&D Day and replay will be available online from the Events and Presentations section of Paratek’s website at A replay of the presentation will be posted on the Paratek website approximately one hour after the live event and will be available for 30 days following the presentation.

About Paratek Pharmaceuticals, Inc. 
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2016 Paratek announced positive efficacy data in a Phase 3 registration study in ABSSSI demonstrating the efficacy and safety of intravenous (IV) to oral omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia (CABP) comparing IV-to-oral omadacycline to IV-to-oral moxifloxacin was initiated in November 2015.  Enrollment continues on track to report top line data as early as the third quarter of 2017.  A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. Top line data are expected as early as the second quarter of 2017. A Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration.

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.

For more information, visit



Michael Lampe
Scient Public Relations
(484) 575-5040

Hans Vitzthum
LifeSci Advisors, LLC.

Primary Logo